Dr. Daniel P. Williams JR., D.O.
Emergency Medicine (Emergency Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 159
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Emergency Medicine Physician primary
SC license 51942 -
General Practice Physician
SC license 51942 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Spartanburg Medical Center Spartanburg, SC
Medical groups
- Spartanburg Medical Center (1,078 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 159
- Services billed
- 232
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 236 | 209 |
| Emergency department visit with high level of medical decision making | 200 | 194 |
| Emergency department visit with moderate level of medical decision making | 172 | 159 |
| Emergency department visit with low level of medical decision making | 66 | 61 |
| Critical care, first 30-74 minutes | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Odt (ondansetron) Other prescribers in Buffalo, NY | 27 |
| Doxycycline Hyclate Other prescribers in Buffalo, NY | 22 |
| Prednisone Other prescribers in Buffalo, NY | 19 |
| Cephalexin Other prescribers in Buffalo, NY | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 12 payments worth $1,489 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $774 |
|---|---|
| Merck Sharp & Dohme LLC | $715 |
| Travel and Lodging | $855 |
|---|---|
| Food and Beverage | $634 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Sep 23, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Atlanta, GA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $238 |
| Novartis Pharmaceuticals Corporation Jun 21, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $214 |
| Merck Sharp & Dohme LLC Oct 6, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Atlanta, GA Company’s descriptionProvided as part of a clinical research engagement. | $193 |
| Novartis Pharmaceuticals Corporation Jun 21, 2025 | Travel and Lodging travel to Atlanta, GA | $193 |
| Novartis Pharmaceuticals Corporation Jun 21, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $17.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $450,248 in research payments for these studies, mostly to the institutions running them.
- A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clini…
AstraZeneca Pharmaceuticals LP - A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients
Novartis Pharmaceuticals Corporation - Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2)
ModernaTX, Inc. - Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APP…
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.